Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Foppoli

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Cancers|January 21, 2023
Diagnosis and Treatment Using Autologous Stem-Cell Transplantation in Primary Central Nervous System Lymphoma: A Systematic ReviewSara Steffanoni, Teresa Calimeri, Sarah Marktel, et al.
Haematologica|September 13, 2003
Questions and answers in the management of primary central nervous system and ocular lymphomasAndrés J M Ferreri, Stefania Dell'oro, Michele Reni, et al.
Expert Opinion on Pharmacotherapy|May 1, 2010
Treatment approaches for primary CNS lymphomasMatteo G Carrabba, Michele Reni, Marco Foppoli, et al.
British Journal of Haematology|October 15, 2014
Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab eraAndrés J M Ferreri, Marta Bruno-Ventre, Giovanni Donadoni, et al.
The Oncologist|February 25, 2011
Clinical relevance of the dose of cytarabine in the upfront treatment of primary CNS lymphomas with methotrexate-cytarabine combinationAndrés J M Ferreri, Giada Licata, Marco Foppoli, et al.
British Journal of Haematology|August 26, 2004
Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomasAndrés J M Ferreri, Stefania Dell'Oro, Daniela Capello, et al.
Haematologica|June 1, 2005
The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1/PDGFRA but not genomic rearrangements of other tyrosine kinasesRoberta La Starza, Giorgina Specchia, Antonio Cuneo, et al.
British Journal of Haematology|August 29, 2012
Safety and activity of a new intensive short-term chemoimmunotherapy in HIV-positive patients with Burkitt lymphomaAndrés J M Ferreri, Marta Bruno Ventre, Giovanni Donadoni, et al.
Hematological Oncology|November 20, 2012
Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapySilvia Mappa, Emerenziana Marturano, Giada Licata, et al.
British Journal of Haematology|October 21, 2020
A dose-dense short-term therapy for human immunodeficiency virus/acquired immunodeficiency syndrome patients with high-risk Burkitt lymphoma or high-grade B-cell lymphoma: safety and efficacy results of the "CARMEN" phase II trialAndrés J M Ferreri, Chiara Cattaneo, Arben Lleshi, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Cancers|January 21, 2023
Diagnosis and Treatment Using Autologous Stem-Cell Transplantation in Primary Central Nervous System Lymphoma: A Systematic ReviewSara Steffanoni, Teresa Calimeri, Sarah Marktel, et al.
Haematologica|September 13, 2003
Questions and answers in the management of primary central nervous system and ocular lymphomasAndrés J M Ferreri, Stefania Dell'oro, Michele Reni, et al.
Expert Opinion on Pharmacotherapy|May 1, 2010
Treatment approaches for primary CNS lymphomasMatteo G Carrabba, Michele Reni, Marco Foppoli, et al.
British Journal of Haematology|October 15, 2014
Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab eraAndrés J M Ferreri, Marta Bruno-Ventre, Giovanni Donadoni, et al.
The Oncologist|February 25, 2011
Clinical relevance of the dose of cytarabine in the upfront treatment of primary CNS lymphomas with methotrexate-cytarabine combinationAndrés J M Ferreri, Giada Licata, Marco Foppoli, et al.
British Journal of Haematology|August 26, 2004
Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomasAndrés J M Ferreri, Stefania Dell'Oro, Daniela Capello, et al.
Haematologica|June 1, 2005
The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1/PDGFRA but not genomic rearrangements of other tyrosine kinasesRoberta La Starza, Giorgina Specchia, Antonio Cuneo, et al.
British Journal of Haematology|August 29, 2012
Safety and activity of a new intensive short-term chemoimmunotherapy in HIV-positive patients with Burkitt lymphomaAndrés J M Ferreri, Marta Bruno Ventre, Giovanni Donadoni, et al.
Hematological Oncology|November 20, 2012
Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapySilvia Mappa, Emerenziana Marturano, Giada Licata, et al.
British Journal of Haematology|October 21, 2020
A dose-dense short-term therapy for human immunodeficiency virus/acquired immunodeficiency syndrome patients with high-risk Burkitt lymphoma or high-grade B-cell lymphoma: safety and efficacy results of the "CARMEN" phase II trialAndrés J M Ferreri, Chiara Cattaneo, Arben Lleshi, et al.
Pageof 3